Comparative analysis of the serum proteome profiles of thyroid cancer: An initial focus on the lipid profile

Li, Dandan; Zhou, Liangrui; Ma, Chaochao; Chen, Wenhu; Zhang, Yimin; Yu, Songlin; Wang, Danchen; Zou, Yutong; Wu, Jie; Qiu, Ling

doi:10.3892/ol.2019.10655

Cited by 23 publications

(45 citation statements)

References 26 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apo-A1 has been proved to be associated with many cancer, furthermore, it could be used as a potential biomarker for detection and diagnosis for many cancers such as bladder cancer [ 16 , 17 ]. In a recent study, researchers observed that lower serum levels of Apo-A1 in thyroid cancer patients compared to healthy controls, indicating that Apo-A1 may play an anti-tumor role in thyroid cancer [ 18 ]. Interestingly, Apo-A1 was showed association with tumor size only in the male group, but not in the female group.…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein A1 is negatively associated with male papillary thyroid cancer patients: a cross-sectional study of single academic center in China

Wang

Zhang

et al. 2021

BMC Endocr Disord

View full text Add to dashboard Cite

Background Papillary thyroid cancer (PTC) is the most common type of thyroid cancer and the incidence of PTC has continued to increase over the past decades. Many studies have shown that obesity is an independent risk factor for PTC and obese PTC patients tend to have a relative larger tumor size and higher grade of tumor stage. Obesity is associated with disordered lipid metabolism and the relationship between serum lipids and PTC remains unclear. Therefore, this study aimed to investigate the association between serum lipid level and PTC. Methods We retrospectively analyzed 1018 PTC patients diagnosed and treated in our hospital, all these cases were first diagnosed with PTC and had complete clinical information including ultrasound reports before surgery, serum lipid (CHOL, TG, HDL-c, LDL-c, Apo-A1, Apo-B, Apo-E) results, surgical records and pathological reports. Results None of these lipid markers were associated with tumor size in the whole cohort and in the female group. In the male group, on crude analysis, Apo-A1 showed a marginally association with tumor size, [OR = 0.158 (0.021–1.777)], p = 0.072. After adjusting for age and multifocality, Apo-A1 showed a significant association with tumor size [OR = 0.126 (0.016–0.974)], p = 0.047. This association become more apparent in a young male subgroup, [OR = 0.051 (0.005–0.497)], p = 0.009. CHOL, TG, HDL-c, LDL-c, Apo-B, Apo-E did not show significant association with tumor size. As for LNM, neither in the male group nor in the female group were found to be associated with any serum lipid biomarkers. Conclusion As PTC incidences continues to increase, our findings demonstrated a negatively association between PTC and apoA-1 in male PTC patients, which may contribute to further investigation concerning diagnosing and preventing this most common type of thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Apolipoprotein A1 is negatively associated with male papillary thyroid cancer patients: a cross-sectional study of single academic center in China

Wang

Zhang

et al. 2021

BMC Endocr Disord

View full text Add to dashboard Cite

show abstract

“…There were eight upregulated (ratio > 2) and nine downregulated proteins (ratio < 0.5) in the TC group compared to those in the non-TC group, with expression ratios (cancer/control) ranging from 0.0433 to 7.799 ( Table S3 ). The results of some screening of the data from the training study were provided in our previous study ( Li et al, 2019 ).…”

Section: Resultsmentioning

confidence: 99%

“…Details regarding the inclusion and exclusion criteria used were provided in a previous study ( Li et al, 2019 ). All blood samples were collected after 9–12 h of overnight fasting before thyroidectomy or a health checkup.…”

Section: Methodsmentioning

confidence: 99%

Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry

Liu

et al. 2020

PeerJ

Self Cite

View full text Add to dashboard Cite

Background Distinguishing between different types of thyroid cancers (TC) remains challenging in clinical laboratories. As different tumor types require different clinical interventions, it is necessary to establish new methods for accurate diagnosis of TC. Methods Proteomic analysis of the human serum was performed through data-independent acquisition mass spectrometry for 29 patients with TC (stages I–IV): 13 cases of papillary TC (PTC), 10 cases of medullary TC (MTC), and six cases follicular TC (FTC). In addition, 15 patients with benign thyroid nodules (TNs) and 10 healthy controls (HCs) were included in this study. Subsequently, 17 differentially expressed proteins were identified in 291 patients with TC, including 247 with PTC, 38 with MTC, and six with FTC, and 69 patients with benign TNs and 176 with HC, using enzyme-linked immunosorbent assays. Results In total, 517 proteins were detected in the serum samples using an Orbitrap Q-Exactive-plus mass spectrometer. The amyloid beta A4 protein, apolipoprotein A-IV, gelsolin, contactin-1, gamma-glutamyl hydrolase, and complement factor H-related protein 1 (CFHR1) were selected for further analysis. The median serum CFHR1 levels were significantly higher in the MTC and FTC groups than in the PTC and control groups (P < 0.001). CFHR1 exhibited higher diagnostic performance in distinguishing patients with MTC from those with PTC (P < 0.001), with a sensitivity of 100.0%, specificity of 85.08%, area under the curve of 0.93, and detection cut-off of 0.92 ng/mL. Conclusion CFHR1 may serve as a novel biomarker to distinguish PTC from MTC with high sensitivity and specificity.

show abstract

“…Apo-A1 has been proved to be associated with many cancer, furthermore, it could be used as a potential biomarker for detection and diagnosis for many cancers such as bladder cancer [15,16]. In a recent study, researchers observed that lower serum levels of Apo-A1 in thyroid cancer patients compared to healthy controls, indicating that Apo-A1 may play an anti-tumor role in thyroid cancer [17]. Similarly, Lp (a) also manifested anti-neoplastic properties in other cancers [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein A1 and lipoprotein(a) are protective factors for male papillary thyroid cancer patients. A cross-sectional study of single academic center in China.

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

KEYWORDSPapillary thyroid cancer, serum lipid level, tumor size, lipid metabolism 2 Abstract Background: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer and the incidence of PTC continued to increase over the past decades. Many studies showed that obesity is an independent risk factor for PTC and obese PTC patients tend to have a relative larger tumor size and higher grade of tumor stage. Obesity is closely related with lipid metabolism, while the correlation between serum lipid and PTC remains unclear. Therefore, this study aimed to investigate the association between serum lipid level and PTC.Methods: We retrospectively analyzed 1018 PTC patients diagnosed and treated in our hospital, all these cases were first diagnosed with PTC and had complete clinical information including ultrasound reports before surgery, serum lipid (CHOL, TG, HDL-c, LDL-c, Apo-A1, Apo-B, Apo-E, Lp (a)) results, surgical records and pathological reports.Results: All these serum lipid biomarkers did not associated with tumor size in the female group. In the male group, on crude analysis, Apo-A1 and Lp (a) showed a marginally significant association with tumor size OR and 95% CI 0.158 (0.021-1.777), p=0.072; 0.997 (0.993-1.000) p=0.082 respectively.After adjusting for age and multifocality, Apo-A1 and Lp (a) showed a significant association with

show abstract

Comparative analysis of the serum proteome profiles of thyroid cancer: An initial focus on the lipid profile

Cited by 23 publications

References 26 publications

Apolipoprotein A1 is negatively associated with male papillary thyroid cancer patients: a cross-sectional study of single academic center in China

Apolipoprotein A1 is negatively associated with male papillary thyroid cancer patients: a cross-sectional study of single academic center in China

Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry

Apolipoprotein A1 and lipoprotein(a) are protective factors for male papillary thyroid cancer patients. A cross-sectional study of single academic center in China.

Contact Info

Product

Resources

About